CytomX Therapeutics upgraded by Piper Sandler with a new price target

5/28/24 7:31:35 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Piper Sandler upgraded CytomX Therapeutics from Neutral to Overweight and set a new price target of $3.50 from $2.25 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CTMX

Date	Price Target	Rating	Analyst
5/15/2025	$5.00	Neutral → Buy	H.C. Wainwright
4/14/2025	$3.25 → $2.50	Overweight	Piper Sandler
5/28/2024	$2.25 → $3.50	Neutral → Overweight	Piper Sandler
5/9/2024	$8.00	Neutral → Outperform	Wedbush
5/6/2024	$2.50 → $8.00	Hold → Buy	Jefferies
4/22/2024		Underweight → Neutral	JP Morgan
11/14/2022	$3.00 → $2.60	Outperform → Market Perform	BMO Capital Markets
7/7/2022	$16.00 → $4.00	Buy → Neutral	Mizuho